The iShares Core High Dividend ETF (HDV) delivers a 3.30% trailing yield with an expense ratio of 0.08%, and manages $11.8 billion in assets. Over the past 12 months, HDV returned 11.3% compared with 17% for the S&P 500, and over a 10-year period it has underperformed by nearly 100 percentage points in price appreciation. With a 14-year track record, HDV appeals to income-focused investors seeking blue-chip dividend payers in consumer staples (28%), energy (24%) and healthcare (17%), but its relative underperformance raises questions about its growth potential versus broader market benchmarks.

HDV’s top five positions account for 28.5% of the fund. Exxon Mobil (9.4% weighting) offers a 3.2% yield with a 58% earnings payout ratio, supporting a dividend that rose 4% in late 2025. Chevron (6.8%) yields 4.1% but pays out 95% of earnings, following a 4.9% hike in early 2025 despite a 27% year-over-year earnings drop. Johnson & Johnson (6.7%) represents a 2.5% yield with a 49% payout ratio after a 4.8% dividend increase in 2025. AbbVie (6.2%) stands out with a 3.0% yield but an unsustainably high 497% payout ratio, reflecting an $89% plunge in quarterly earnings as Humira faces patent challenges. Procter & Gamble (5.4%) rounds out the top five with a 2.9% yield and a 60% payout ratio, offering greater stability with 20% profit margins.

HDV’s quarterly distributions fluctuate sharply, from $0.795 in Q1 2025 to $1.253 in Q4 2025—a 58% swing. Total dividend distributions fell 4.9% to $3.91 per share in 2025, down from $4.11 in 2024. Over the past decade, HDV’s dividend growth has averaged just 3.1% annually, barely outpacing inflation. This volatility, combined with concentrated sector exposure and underwhelming total returns versus major indices, highlights the risks retirees face when relying on HDV for stable income without supplementary diversification strategies.